Therapeutic outcomes of glofitamab-based regimens in Chinese patients with Relapsed/Refractory B-cell lymphoma: A single-center retrospective real-world study
Retrospective analysis indicates glofitamab improves response rates in Chinese patients with R/R B-cell lymphoma, suggesting a promising treatment option.
Key Points
Evaluating the therapeutic outcomes of glofitamab-based regimens in Chinese patients with relapsed/refractory B-cell lymphoma.
Conducted a single-center retrospective study in a Chinese hospital.
Enrolled patients with R/R B-cell lymphoma receiving glofitamab-based therapy.
Collected comprehensive clinical data, including treatment details and adverse events.
Among 20 patients, the overall response rate was 92.8%, with a 35.7% complete response rate.
Treatment included glofitamab monotherapy and combination regimens with chemotherapy.
Reported adverse events included grade 1 cytokine release syndrome in 7 patients and grade 3 lymphopenia in 12 patients.